تحلیل اختیاری محصول
با اجازه شما، از تحلیلهای محدود و حریمخصوصیمحور استفاده میکنیم تا مسیرهای پژوهشی مؤثر را بشناسیم. از ردیاب تبلیغاتی یا بازپخش نشست استفاده نمیکنیم. این انتخاب را میتوانید در تنظیمات تغییر دهید. بخوانید سیاست حفظ حریم خصوصی.
Labcorp Holdings Inc.'s published Reduce conclusion compares the analysis-date price with fair value and potential value. Read the full report for assumptions, evidence, and material risks.
| Market cap | $25.3B | |
|---|---|---|
| Revenue (ttm) | 14.6B | |
| Net income (ttm) | 1B | |
| EPS (ttm) | $12.2 | |
| Shares out | 81.1M | |
| P/E (trailing) | 29.6x | |
| P/E (forward) | 16.2x | |
| Dividend | $2.88 (0.80%) | |
| Volume | 1,610,966 | |
| Beta | 0.85 |
Recent price action with selectable time range.
| Item | P1 | P2 | P3 | P4 | P5 | Trend |
|---|---|---|---|---|---|---|
| Period | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 | Trend |
| Revenue | $13.14B | $11.86B | $12.16B | $13.01B | $13.95B | +1.5% |
| Gross profit | $4.99B | $3.71B | $3.36B | $3.62B | $4.01B | -5.3% |
| Operating income | $3.05B | $1.44B | $725.6M | $1.09B | $1.38B | -17.9% |
| Net income | $2.38B | $1.28B | $418.0M | $746.0M | $876.5M | -22.1% |
| EPS (diluted) | $24.39 | $13.97 | $4.77 | $8.84 | $10.46 | -19.1% |
| EBITDA | $3.68B | $1.95B | $1.35B | $1.81B | $2.01B | -14.0% |
| R&D | — | — | $2.0M | — | — | — |
| SG&A | $1.69B | $1.76B | $2.02B | $2.23B | $2.22B | +7.0% |
Recent company headlines from major financial publishers.
In the base case modal path, Labcorp compounds revenue at 5.72% in FY2026 ($14,749.3M) and 4.95% in FY2027 ($15,479.5M), before tapering toward 4.2% across the forecast horizon. Consolidated operating margin expands moderately from 9.92% in FY2025 to 10.44% in FY2026 and 11.66% by FY2030. High free cash flow conversion ($1,206.0M in FY2025) supports ongoing share repurchases and debt service, yielding an intrinsic fair value of $263.85.
In the bull scenario, high-complexity testing volume accelerates across oncology, women's health, and neurology, while direct-to-consumer testing through Labcorp OnDemand sustains double-digit expansion with upfront payment collection. Biopharma Laboratory Services achieves substantial operating leverage as Central Labs trial volumes expand and Early Development restructuring takes hold. Consolidated operating margins expand toward 11.8% to 12.0%, supporting valuation toward the high end of intrinsic value at $335.23.
| Ke ↓ / g → | 2.0% | 2.3% | 2.5% | 2.8% | 3.0% |
|---|---|---|---|---|---|
| 8.0% | $283 | $289 | $296 | $304 | $312 |
| 8.5% | $268 | $273 | $279 | $285 | $292 |
| 9.0% | $255 | $259 | $264 | $269 | $275 |
| 9.5% | $244 | $247 | $251 | $255 | $260 |
| 10.0% | $234 | $237 | $240 | $244 | $248 |
Upcoming earnings date and setup when available.
رتبهای که نسخهٔ پژوهشی منتشرشدهٔ هر ماه داشت. رتبه قیمت در تاریخ تحلیل را با ارزش منصفانه مقایسه میکند و سابقهای از درستی یا نادرستی ارزیابی نیست.
| سال | دی | بهمن | اسفند | فروردین | اردیبهشت | خرداد | تیر | مرداد | شهریور | مهر | آبان | آذر |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 |
